Quest Dx buys UMass labs; Abbott completes AbbVie spinout;

 @FierceMedDev: Diabetes light Dx begins U.S. trial. Story | Follow @FierceMedDev

@MarkHFierce: Dune Medical won an FDA nod for a new tool designed to find cancerous tissue. The company is a rumored M&A target. Report | Follow @MarkHFierce

 @DamianFierce: DJO Global scoops up Minnesota maker of heat-sensitive casts. More | Follow @DamianFierce

> Quest Diagnostics ($DGX) has acquired clinical outreach laboratory and anatomic pathology outreach laboratory businesses from the UMass Memorial Medical Center, planning to roll the units into its operations and lease 200,000 square feet of clinical space from the school. Release

> Johnson & Johnson's ($JNJ) Ortho-Clinical Diagnostics has sold its Therakos business to the Gores Group for an undisclosed sum. More

> Mallinckrodt, Covidien's ($COV) pharma business, got FDA approval to start manufacturing and selling a generic version of the ADHD drug Concerta. Covidien is planning to spin its drug business out this year. Item

> Abbot Laboratories ($ABT) has completed its corporate mitosis, launching the drug-developing AbbVie ($ABBV) and keeping its devices, diagnostics and branded generics under the old moniker. News

> Smith & Nephew ($SNN) closed its $782 million buyout of Healthpoint, maker of bioactive wound therapy products. More

> Ohio's AtriCure ($ATRC) is working with NineSigma to streamline its technology, part of a state-funded effort to help local business increase their profitability. Article

> In the U.K., many are signing up for a molecular diagnostic test that claims to predict how long patients will live, but many experts say the science behind the assay is dubious at best. Story

> Neogen ($NEOG) has acquired Scidera Genomics, a specialist in animal diagnostics, for an undisclosed sum. Release

Biotech News

 @FierceBiotech: Preclinical breast cancer finding could change tamoxifen use. Story | Follow @FierceBiotech

@JohnCFierce: It's official. 39 new drugs approved in 2012, highest since 1996. Big step in the right direction. More | Follow @JohnCFierce

@RyanMFierce: Qualcomm backs clinical trials software outfit in $12M round. News | Follow @RyanMFierce

> AbbVie celebrates New Year's Day as a big new biopharma player. Report

> New cancer drugs help spur drug approvals to 16-year high. Story

Pharma News

@FiercePharma: AbbVie is pharma's first birth of the new year. Story | Follow @FiercePharma

> Sun chief eyes more deals, European and otherwise. News

> Cancer meds now drugs of choice among counterfeiters . Article

CRO News

> India group wants change in clinical trial regs for children. Report

> WuXi, PRA plan to launch joint venture in China. News

> Chinese CRO ShangPharma looks to go private. Article

> goBalto rakes in $12M for cloud-based clinical development. Story

Biotech IT News

> Interview: Stanford's Butte on bridging gap from Big Data to biotech discoveries. Item

> iPad app garners kudos for boosting lab productivity. Article

> iPad app garners kudos for boosting lab productivity. News

> Qualcomm backs clinical trials software outfit in $12M round. Story

Biotech Research News

> Preclinical breast cancer finding could change tamoxifen use. Item

> Enzyme inhibitor could be key to treating malaria. Report

> Scripps drug reduces, reverses fatty liver disease. News

> Chemo combo shows promise against glioblastoma. Article

> Stem cells step forward in ALS. Story

Drug Delivery News

> Radius, 3M update transdermal osteoporosis treatment agreement. News

> Arrowhead polymers boost siRNA delivery 500 times. Story

> Japan welcomes Neupro patch for restless legs and Parkinson's. Article

> QLT signs eye delivery tech option deal with former CEO. Report

> AstraZeneca hitches cancer drug hopes to CytImmune's nano-gold standard. Item

Suggested Articles

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.